Nirali N Shah1, Daniel W Lee1,2, Bonnie Yates1, Constance M Yuan3,4, Haneen Shalabi1, Staci Martin1, Pamela L Wolters1, Seth M Steinberg5, Eva H Baker6, Cindy P Delbrook1, Maryalice Stetler-Stevenson3,4, Terry J Fry1,7, David F Stroncek8, Crystal L Mackall1,9,10,11. 1. Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD. 2. Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA. 3. Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD. 4. Oncogenomics Section, Genetics Branch, NCI, Bethesda, MD. 5. Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, Bethesda, MD. 6. Department of Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD. 7. Division of Human Immunology and Immunotherapy Initiative, Pediatric Hematology/Oncology, Children's Hospital of Colorado, Aurora, CO. 8. Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD. 9. Department of Pediatrics, Stanford University, Stanford, CA. 10. Department of Medicine, Stanford University, Stanford, CA. 11. Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA.
Abstract
PURPOSE: CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high. The role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy to improve long-term outcomes in CAYAs has not been examined. METHODS: We conducted a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL. Response and long-term clinical outcomes were assessed in relation to disease and treatment variables. RESULTS: Fifty CAYAs with B-ALL were treated (median age, 13.5 years; range, 4.3-30.4). Thirty-one (62.0%) patients achieved a complete remission (CR), 28 (90.3%) of whom were minimal residual disease-negative by flow cytometry. Utilization of fludarabine/cyclophosphamide-based lymphodepletion was associated with improved CR rates (29/42, 69%) compared with non-fludarabine/cyclophosphamide-based lymphodepletion (2/8, 25%; P = .041). With median follow-up of 4.8 years, median overall survival was 10.5 months (95% CI, 6.3 to 29.2 months). Twenty-one of 28 (75.0%) patients achieving a minimal residual disease-negative CR proceeded to alloHSCT. For those proceeding to alloHSCT, median overall survival was 70.2 months (95% CI, 10.4 months to not estimable). The cumulative incidence of relapse after alloHSCT was 9.5% (95% CI, 1.5 to 26.8) at 24 months; 5-year EFS following alloHSCT was 61.9% (95% CI, 38.1 to 78.8). CONCLUSION: We provide the longest follow-up in CAYAs with B-ALL after CD19-CAR T-cell therapy reported to date and demonstrate that sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT can mediate durable disease control in a sizable fraction of CAYAs with relapsed or refractory B-ALL (ClinicalTrials.gov identifier: NCT01593696).
PURPOSE: CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high. The role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy to improve long-term outcomes in CAYAs has not been examined. METHODS: We conducted a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL. Response and long-term clinical outcomes were assessed in relation to disease and treatment variables. RESULTS: Fifty CAYAs with B-ALL were treated (median age, 13.5 years; range, 4.3-30.4). Thirty-one (62.0%) patients achieved a complete remission (CR), 28 (90.3%) of whom were minimal residual disease-negative by flow cytometry. Utilization of fludarabine/cyclophosphamide-based lymphodepletion was associated with improved CR rates (29/42, 69%) compared with non-fludarabine/cyclophosphamide-based lymphodepletion (2/8, 25%; P = .041). With median follow-up of 4.8 years, median overall survival was 10.5 months (95% CI, 6.3 to 29.2 months). Twenty-one of 28 (75.0%) patients achieving a minimal residual disease-negative CR proceeded to alloHSCT. For those proceeding to alloHSCT, median overall survival was 70.2 months (95% CI, 10.4 months to not estimable). The cumulative incidence of relapse after alloHSCT was 9.5% (95% CI, 1.5 to 26.8) at 24 months; 5-year EFS following alloHSCT was 61.9% (95% CI, 38.1 to 78.8). CONCLUSION: We provide the longest follow-up in CAYAs with B-ALL after CD19-CAR T-cell therapy reported to date and demonstrate that sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT can mediate durable disease control in a sizable fraction of CAYAs with relapsed or refractory B-ALL (ClinicalTrials.gov identifier: NCT01593696).
Authors: Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245
Authors: Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall Journal: Lancet Date: 2014-10-13 Impact factor: 79.321
Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808
Authors: Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain Journal: Blood Date: 2011-08-17 Impact factor: 22.113
Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Meghan L Good; Parisa Malekzadeh; Isaac R Kriley; Nirali N Shah; David E Kleiner; Katherine Calvo; Jonathan M Hernandez; Jeremy L Davis Journal: Pediatr Transplant Date: 2020-01-16
Authors: Regina M Myers; Agne Taraseviciute; Seth M Steinberg; Adam J Lamble; Jennifer Sheppard; Bonnie Yates; Alexandra E Kovach; Brent Wood; Michael J Borowitz; Maryalice Stetler-Stevenson; Constance M Yuan; Vinodh Pillai; Toni Foley; Perry Chung; Lee Chen; Daniel W Lee; Colleen Annesley; Amanda DiNofia; Stephan A Grupp; Samuel John; Deepa Bhojwani; Patrick A Brown; Theodore W Laetsch; Lia Gore; Rebecca A Gardner; Susan R Rheingold; Michael A Pulsipher; Nirali N Shah Journal: J Clin Oncol Date: 2021-11-12 Impact factor: 44.544
Authors: Yimei Li; Wei-Ting Hwang; Shannon L Maude; David T Teachey; Noelle V Frey; Regina M Myers; Allison Barz Leahy; Hongyan Liu; David L Porter; Stephan A Grupp; Pamela A Shaw Journal: Clin Cancer Res Date: 2022-09-15 Impact factor: 13.801
Authors: Jonas W Ravich; Sujuan Huang; Yinmei Zhou; Patrick Brown; Ching-Hon Pui; Hiroto Inaba; Cheng Cheng; Stephen Gottschalk; Brandon M Triplett; Challice L Bonifant; Aimee C Talleur Journal: Transplant Cell Ther Date: 2021-12-04
Authors: Daniel A Lichtenstein; Fiorella Schischlik; Lipei Shao; Seth M Steinberg; Bonnie Yates; Hao-Wei Wang; Yanyu Wang; Jon Inglefield; Alina Dulau-Florea; Francesco Ceppi; Leandro C Hermida; Kate Stringaris; Kim Dunham; Philip Homan; Parthav Jailwala; Justin Mirazee; Welles Robinson; Karen M Chisholm; Constance Yuan; Maryalice Stetler-Stevenson; Amanda K Ombrello; Jianjian Jin; Terry J Fry; Naomi Taylor; Steven L Highfill; Ping Jin; Rebecca A Gardner; Haneen Shalabi; Eytan Ruppin; David F Stroncek; Nirali N Shah Journal: Blood Date: 2021-12-16 Impact factor: 22.113